메뉴 건너뛰기




Volumn 377, Issue 12, 2017, Pages 1119-1131

Antiinflammatory therapy with canakinumab for atherosclerotic disease

(2,097)  Ridker, P M a   Everett, B M a   Thuren, T b   MacFadyen, J G a   Chang, W H b   Ballantyne, C c   Fonseca, F d   Nicolau, J e   Koenig, W g   Anker, S D h   Kastelein, J J P i   Cornel, J H j   Pais, P l   Pella, D m   Genest, J n   Cifkova, R o   Lorenzatti, A p   Forster, T q   Kobalava, Z r   Vida Simiti, L s   more..


Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; PLACEBO; ANTIINFLAMMATORY AGENT; INTERLEUKIN 1BETA; LIPID; MONOCLONAL ANTIBODY;

EID: 85029568219     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1707914     Document Type: Article
Times cited : (6528)

References (39)
  • 1
    • 0033552883 scopus 로고    scopus 로고
    • Atherosclerosis — An inflammatory disease
    • Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999;340: 115-26.
    • (1999) N Engl J Med , vol.340 , pp. 115-126
    • Ross, R.1
  • 2
    • 17644412023 scopus 로고    scopus 로고
    • Inflammation, atherosclerosis, and coronary artery disease
    • Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
    • (2005) N Engl J Med , vol.352 , pp. 1685-1695
    • Hansson, G.K.1
  • 3
    • 70450189795 scopus 로고    scopus 로고
    • Inflammation in atherosclerosis: From patho-physiology to practice
    • Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from patho-physiology to practice. J Am Coll Cardiol 2009;54:2129-38.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 2129-2138
    • Libby, P.1    Ridker, P.M.2    Hansson, G.K.3
  • 4
    • 0030956673 scopus 로고    scopus 로고
    • Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
    • Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
    • (1997) N Engl J Med , vol.336 , pp. 973-979
    • Ridker, P.M.1    Cushman, M.2    Stampfer, M.J.3    Tracy, R.P.4    Hennekens, C.H.5
  • 5
    • 0034704893 scopus 로고    scopus 로고
    • C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
    • Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
    • (2000) N Engl J Med , vol.342 , pp. 836-843
    • Ridker, P.M.1    Hennekens, C.H.2    Buring, J.E.3    Rifai, N.4
  • 6
    • 0032169240 scopus 로고    scopus 로고
    • Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
    • Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
    • (1998) Circulation , vol.98 , pp. 839-844
    • Ridker, P.M.1    Rifai, N.2    Pfeffer, M.A.3
  • 7
    • 0035963529 scopus 로고    scopus 로고
    • Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    • Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
    • (2001) N Engl J Med , vol.344 , pp. 1959-1965
    • Ridker, P.M.1    Rifai, N.2    Clearfield, M.3
  • 8
    • 19944429519 scopus 로고    scopus 로고
    • Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    • Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
    • (2005) N Engl J Med , vol.352 , pp. 29-38
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 9
    • 11344279659 scopus 로고    scopus 로고
    • C-reactive protein levels and outcomes after statin therapy
    • Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8.
    • (2005) N Engl J Med , vol.352 , pp. 20-28
    • Ridker, P.M.1    Cannon, C.P.2    Morrow, D.3
  • 10
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.H.3
  • 11
    • 84953425720 scopus 로고    scopus 로고
    • Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simva-statin and associated with better outcomes in IMPROVE-IT
    • Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simva-statin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132:1224-33.
    • (2015) Circulation , vol.132 , pp. 1224-1233
    • Bohula, E.A.1    Giugliano, R.P.2    Cannon, C.P.3
  • 12
    • 66649102432 scopus 로고    scopus 로고
    • Use of canakinumab in the cryopyrin-associated periodic syndrome
    • Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
    • (2009) N Engl J Med , vol.360 , pp. 2416-2425
    • Lachmann, H.J.1    Kone-Paut, I.2    Kuemmerle-Deschner, J.B.3
  • 13
    • 84871318830 scopus 로고    scopus 로고
    • Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
    • Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
    • (2012) N Engl J Med , vol.367 , pp. 2396-2406
    • Ruperto, N.1    Brunner, H.I.2    Quartier, P.3
  • 14
    • 84870619337 scopus 로고    scopus 로고
    • Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrin-ogen: A phase IIb randomized, placebo-controlled trial
    • Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrin-ogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126: 2739-48.
    • (2012) Circulation , vol.126 , pp. 2739-2748
    • Ridker, P.M.1    Howard, C.P.2    Walter, V.3
  • 15
    • 80053644777 scopus 로고    scopus 로고
    • Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
    • Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.
    • (2011) Am Heart J , vol.162 , pp. 597-605
    • Ridker, P.M.1    Thuren, T.2    Zalewski, A.3    Libby, P.4
  • 16
    • 85029555284 scopus 로고    scopus 로고
    • Effects of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind placebo-controlled trial
    • in press
    • Ridker PM, MacFadyen JG, Thuren T, Everett B, Libby P, Glynn RJ. Effects of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind placebo-controlled trial. Lancet (in press).
    • Lancet
    • Ridker, P.M.1    MacFadyen, J.G.2    Thuren, T.3    Everett, B.4    Libby, P.5    Glynn, R.J.6
  • 17
    • 79953813107 scopus 로고    scopus 로고
    • Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
    • Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32.
    • (2011) Blood , vol.117 , pp. 3720-3732
    • Dinarello, C.A.1
  • 18
    • 84864545087 scopus 로고    scopus 로고
    • Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
    • Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52.
    • (2012) Nat Rev Drug Discov , vol.11 , pp. 633-652
    • Dinarello, C.A.1    Simon, A.2    Van Der Meer, J.W.M.3
  • 19
    • 0022494648 scopus 로고
    • Endo-toxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells
    • Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. Endo-toxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 1986;124:179-85.
    • (1986) Am J Pathol , vol.124 , pp. 179-185
    • Libby, P.1    Ordovas, J.M.2    Auger, K.R.3    Robbins, A.H.4    Birinyi, L.K.5    Dinarello, C.A.6
  • 20
    • 0037388984 scopus 로고    scopus 로고
    • Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice
    • Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003;23: 656-60.
    • (2003) Arterioscler Thromb Vasc Biol , vol.23 , pp. 656-660
    • Kirii, H.1    Niwa, T.2    Yamada, Y.3
  • 21
    • 0030020406 scopus 로고    scopus 로고
    • Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vaso-spastic responses in pigs in vivo: The role of platelet-derived growth factor
    • Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vaso-spastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest 1996;97:769-76.
    • (1996) J Clin Invest , vol.97 , pp. 769-776
    • Shimokawa, H.1    Ito, A.2    Fukumoto, Y.3
  • 22
    • 77951800951 scopus 로고    scopus 로고
    • NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
    • Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
    • (2010) Nature , vol.464 , pp. 1357-1361
    • Duewell, P.1    Kono, H.2    Rayner, K.J.3
  • 23
    • 77955356552 scopus 로고    scopus 로고
    • Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation
    • Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010;5(7):e11765.
    • (2010) Plos One , vol.5 , Issue.7
    • Rajamäki, K.1    Lappalainen, J.2    Oörni, K.3
  • 24
    • 84881131862 scopus 로고    scopus 로고
    • Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endo-thelium mediates hemodynamic-induced atherosclerosis susceptibility
    • Xiao H, Lu M, Lin TY, et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endo-thelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 2013;128:632-42.
    • (2013) Circulation , vol.128 , pp. 632-642
    • Xiao, H.1    Lu, M.2    Lin, T.Y.3
  • 25
    • 84917736664 scopus 로고    scopus 로고
    • Moderate hypoxia potentiates interleukin-1β production in activated human macrophages
    • Folco EJ, Sukhova GK, Quillard T, Libby P. Moderate hypoxia potentiates interleukin-1β production in activated human macrophages. Circ Res 2014;115:875-83.
    • (2014) Circ Res , vol.115 , pp. 875-883
    • Folco, E.J.1    Sukhova, G.K.2    Quillard, T.3    Libby, P.4
  • 26
    • 84859215358 scopus 로고    scopus 로고
    • The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis
    • The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012;379:1214-24.
    • (2012) Lancet , vol.379 , pp. 1214-1224
  • 27
    • 84859210770 scopus 로고    scopus 로고
    • Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies
    • IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-13.
    • (2012) Lancet , vol.379 , pp. 1205-1213
  • 28
    • 84947487872 scopus 로고    scopus 로고
    • Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction
    • Sager HB, Heidt T, Hulsmans M, et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 2015;132:1880-90.
    • (2015) Circulation , vol.132 , pp. 1880-1890
    • Sager, H.B.1    Heidt, T.2    Hulsmans, M.3
  • 29
    • 85010198872 scopus 로고    scopus 로고
    • Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
    • Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017;355:842-7.
    • (2017) Science , vol.355 , pp. 842-847
    • Fuster, J.J.1    MacLauchlan, S.2    Zuriaga, M.A.3
  • 30
    • 85023756316 scopus 로고    scopus 로고
    • Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
    • Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111-21.
    • (2017) N Engl J Med , vol.377 , pp. 111-121
    • Jaiswal, S.1    Natarajan, P.2    Silver, A.J.3
  • 31
    • 85009785723 scopus 로고    scopus 로고
    • Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states
    • Furman D, Chang J, Lartigue L, et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med 2017;23:174-84.
    • (2017) Nat Med , vol.23 , pp. 174-184
    • Furman, D.1    Chang, J.2    Lartigue, L.3
  • 32
    • 84976444896 scopus 로고    scopus 로고
    • Residual inflammatory risk: Addressing the obverse side of the atherosclerosis prevention coin
    • Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016;37:1720-2.
    • (2016) Eur Heart J , vol.37 , pp. 1720-1722
    • Ridker, P.M.1
  • 33
    • 85017341929 scopus 로고    scopus 로고
    • Evolocumab and clinical outcomes in patients with cardiovascular disease
    • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
    • (2017) N Engl J Med , vol.376 , pp. 1713-1722
    • Sabatine, M.S.1    Giugliano, R.P.2    Keech, A.C.3
  • 34
    • 85018314556 scopus 로고    scopus 로고
    • Cardiovascular efficacy and safety of boco-cizumab in high-risk patients
    • Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of boco-cizumab in high-risk patients. N Engl J Med 2017;376:1527-39.
    • (2017) N Engl J Med , vol.376 , pp. 1527-1539
    • Ridker, P.M.1    Revkin, J.2    Amarenco, P.3
  • 35
    • 84928230527 scopus 로고    scopus 로고
    • The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study
    • Morton AC, Rothman AMK, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015;36:377-84.
    • (2015) Eur Heart J , vol.36 , pp. 377-384
    • Morton, A.C.1    Rothman, A.M.K.2    Greenwood, J.P.3
  • 37
    • 84904543855 scopus 로고    scopus 로고
    • Anti-inflammatory therapies for cardiovascular disease
    • Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-91.
    • (2014) Eur Heart J , vol.35 , pp. 1782-1791
    • Ridker, P.M.1    Lüscher, T.F.2
  • 38
    • 33845546703 scopus 로고    scopus 로고
    • The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
    • Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;25:387-408.
    • (2006) Cancer Metastasis Rev , vol.25 , pp. 387-408
    • Apte, R.N.1    Dotan, S.2    Elkabets, M.3
  • 39
    • 77950346282 scopus 로고    scopus 로고
    • Immunity, inflammation, and cancer
    • Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
    • (2010) Cell , vol.140 , pp. 883-899
    • Grivennikov, S.I.1    Greten, F.R.2    Karin, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.